To develop a potent therapeutic marburgvirus monoclonal antibody.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93021C00021
- Awardee
-
Abvacc, Inc. UEI K5MSGRFGVVZ9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,467,335
Award facts
- Opportunity
-
- 2020 NIAID Omnibus Broad Agency Announcement Pre-Solicitation · HHSNIHNIAIDBAA20201 · Posted Dec 11, 2019
- 2020 NIAID Omnibus Broad Agency Announcement Award Notice · Posted May 12, 2021
- 2020 NIAID Omnibus Broad Agency Announcement Solicitation · Posted Jan 3, 2020
- Contract value 20% obligated
-
- $3,467,334.76 Current, with exercised options
- $16,927,478.76 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 23 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $21,963 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $69,231 | |
| Novation Agreement | $0 | |
| Funding Only Action | $553,439 | |
| Exercise an Option | $1,073,334 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,749,368 |
Show all 12
About this award
This is a $16,927,478.76 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Abvacc, Inc., a for-profit biotechnology company. The contract is to develop a potent therapeutic monoclonal antibody targeting the Marburg virus, a highly pathogenic filovirus. This award aligns with NIAID's efforts to advance medical countermeasures against biodefense and emerging infectious disease threats. The contract, which has no set-aside designation, will be executed in Potomac, Maryland and runs through April 2025. This award leverages NIAID's Omnibus Broad Agency Announcement, which solicits proposals for various vaccine, therapeutic, and diagnostic development projects to address priority pathogens. Abvacc has received prior NIAID funding, including grants focused on Marburg virus countermeasures and research on protective immune responses.
Quick answers
Who was awarded contract 75N93021C00021?
75N93021C00021 was awarded to Abvacc, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 17, 2021.
How much is contract 75N93021C00021 worth?
The government has obligated $3,467,335 on 75N93021C00021. Its potential value, with all options, is $16,927,479.
Was contract 75N93021C00021 competed?
The extent of competition for 75N93021C00021 was full and open competition. The government received 23 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award